指南与共识消化系统肿瘤

美国早发性结直肠癌患者接受指南一致性治疗的种族差异

Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer in the United States.
指南 / 共识 · J Clin Oncol · 2023-11-08

研究基于美国国家癌症数据库2004—2019年确诊的18—49岁早发性结直肠癌患者,比较自我认同为非西班牙裔黑人与白人在接受及时且符合指南的治疗上的差异。黑人患者未接受指南一致性治疗的风险更高,保险因素解释了结肠癌差异的28.2%和直肠癌差异的21.6%。

要点

  • 黑人早发性结肠癌患者未接受指南一致性治疗的校正OR为1.18(95%CI 1.14—1.22)。
  • 黑人早发性直肠癌患者未接受指南一致性治疗的校正OR为1.27(95%CI 1.21—1.33)。
  • 保险是可改变因素,解释结肠癌差异28.2%、直肠癌差异21.6%。

核心结论

  • 黑人早发性结直肠癌患者接受的治疗更差且更不及时;保险是本研究中指南一致性治疗种族差异的最大贡献因素。

研究设计与样本

  • 从美国国家癌症数据库选取2004—2019年新诊断的18—49岁自我认同为非西班牙裔黑人和白人的结直肠癌患者。
  • 接受推荐治疗(分期、手术、淋巴结评估、化疗和放疗)者被视为接受了指南一致性治疗。
  • 采用分解法估计人口学特征(年龄和性别)、合并症、医疗保险和机构类型对指南一致性治疗种族差异的相对贡献;采用乘积限法评估黑人与白人患者至治疗时间的差异。

主要发现

  • 结肠癌84,882例中20.8%为黑人,直肠癌62,573例中14.5%为黑人。
  • 黑人患者未接受指南一致性治疗的风险更高:结肠癌校正OR 1.18(95%CI 1.14—1.22),直肠癌校正OR 1.27(95%CI 1.21—1.33)。
  • 医疗保险分别解释结肠癌和直肠癌患者差异的28.2%和21.6%。
  • 与白人相比,黑人结肠癌患者至辅助化疗时间延长(HR 1.28,95%CI 1.24—1.32),直肠癌患者至新辅助化放疗时间延长(HR 1.42,95%CI 1.37—1.47)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Young individuals racialized as Black are more likely to die after a colorectal cancer (CRC) diagnosis than individuals racialized as White in the United States. This study examined racial disparities in receipt of timely and guideline-concordant care among individuals racialized as Black and White with early-onset CRC. METHODS: Individuals age 18-49 years racialized as non-Hispanic Black and White (self-identified) and newly diagnosed with CRC during 2004-2019 were selected from the National Cancer Database. Patients who received recommended care (staging, surgery, lymph node evaluation, chemotherapy, and radiotherapy) were considered to have received guideline-concordant care. Odds ratios (ORs) were adjusted for age and sex. The decomposition method was used to estimate the relative contribution of demographic characteristics (age and sex), comorbidities, health insurance, and facility type to the racial disparity in receipt of guideline-concordant care. The product-limit method was used to evaluate differences in time to treatment between patients racialized as Black and White. RESULTS: Of the 84,882 patients with colon cancer and 62,573 patients with rectal cancer, 20.8% and 14.5% were racialized as Black, respectively. Individuals racialized as Black were more likely to not receive guideline-concordant care for colon (adjusted OR [aOR], 1.18 [95% CI, 1.14 to 1.22]) and rectal (aOR, 1.27 [95% CI, 1.21 to 1.33]) cancers. Health insurance explained 28.2% and 21.6% of the disparity among patients with colon and rectal cancer, respectively. Individuals racialized as Black had increased time to adjuvant chemotherapy for colon cancer (hazard ratio [HR], 1.28 [95% CI, 1.24 to 1.32]) and neoadjuvant chemoradiation for rectal cancer (HR, 1.42 [95% CI, 1.37 to 1.47]) compared with individuals racialized as White. CONCLUSION: Patients with early-onset CRC racialized as Black receive worse and less timely care than individuals racialized as White. Health insurance, a modifiable factor, was the largest contributor to racial disparities in receipt of guideline-concordant care in this study.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nogueira LM, May FP, Yabroff KR, et al. Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer in the United States. J Clin Oncol. 2023. PMID: 37939323. doi:10.1200/JCO.23.00539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。